Avi Aronov

UIC ➡️ VUMC. Cardiology fellow with an absolute passion for Preventive Cardiology. All tweets are my own.

[Avi Aronov @avi_aronov]

@Drlipid @MichaelAlbertMD @Drlipid Do you mind explaining why?

[Avi Aronov @avi_aronov]

@Drlipid @CVOMed @alanbrownmd @CBallantyneMD @EugeniaGianos @lipiddoc @dan_soffer But why does upstream inhibition in cholesterol synthesis pathway (i.e. bempedoic acid) lead to such markedly reduced LDL compared to downstream inhibition (i.e. statins)? Alternative pathway? What am I missing?

[Dan Soffer @dan_soffer]

Optimal Prescribing of Statins to Reduce Cardiovascular Disease - The American Journal of Medicine https://t.co/rxND9Y3XA8
Agreed!

[Alexander C. Razavi @AlexRazavi]

Nontraditional Risk Markers for Incident CAC Among Persons ≥65 Years of Age @JACCJournals #JACCAdvances

https://t.co/SUJuX1vr66

Identification of albuminuria or extracoronary atherosclerosis may help guide the timing of repeat CAC scoring in older persons with baseline CAC=0

[Paul Sax @PaulSaxMD]

REPRIEVE: Significant decrease in major adverse cardiovascular events with pitavastin.

RCT trial enrolled only low-to-moderate CV risk PWH, for whom a statin might not otherwise be prescribed.

Important clinical trial with direct relevance to pt care. https://t.co/dVtQgtAGhz

[Journal of Clinical Lipidology @LipidJournal]

Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of atherosclerosis @nationallipid @CandaceLJackson @Lpa_Doc @hsbhatia
👉https://t.co/8WIsd7KkJY

[Adam Cifu @adamcifu]

Critically important data.
https://t.co/u94r2VelCG

[Søren Zöga Diederichsen @SZDiederichsen]

#EPeeps #CardioTwitter This deserves A LOT more attention

It's equally promosing and controversial

@CircAHA Article by rising star🌟 @lucas_yxing:
https://t.co/iHB0LL24Xi

Also an example on how to properly conclude on a study @djc795 @drjohnm

Short🧵

1/

[Avi Aronov @avi_aronov]

@anish_koka Observational studies are great for prognostics and natural disease course.

[Adam Mikolajczyk @AdamMikMD]

🔥🔥🔥Wow!!!! In a phenomenally bold wager our Doctor’s Dilemma team won the ACP ILN competition for the 2nd year in a row!!!! Look out San Diego here they come!!! 🎉👏@IllinoisACP @ACPinternists @UICIMChiefs @UIHealth #UICfamily

[Adam Cifu @adamcifu]

Such a good one.
"Some observational studies are correct-- I just don't know which ones."
Study of the Week - Lessons from a Serious Medical Mistake https://t.co/u5ppgSQuNo

[Avi Aronov @avi_aronov]

Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction | NEJM https://t.co/Auk2Qrsu6p

[Dan Leisman, MD, MSCR @danleisman]

(1/ )Summaries of the average high impact trial by field:
#EBM #medtwitter #epitwitter #FOAMed

#Cardiology:We enrolled the entire population of Europe in a trial to detect a composite endpoint occurring in 3% of patients. The relative risk reduction was 20%. The NNT is 12,000

[Avi Aronov @avi_aronov]

Let’s go!!!! 🔥🔥🔥🔥

[IllinoisACP @IllinoisACP]

ACP IL Northern Team @UICDom progresses to the Semi-Final Round of the @ACPinternists Doctor’s Dilemma competition. @avi_aronov @UICIMChiefs

[Avi Aronov @avi_aronov]

@pnatarajanmd @NEJM Such important info — risk prediction in childhood. Would love to see the inclusion of SDOH in childhood on long term outcomes in this cohort.

[Adhir Shroff @AdhirShroff]

@MSAmbalavanan @UIHealth @uiccom @ACCinTouch @PSreepathyMD @UICIMChiefs @NoreenNazirMD @KhalilIbrahimMD @spiritus_bah @StephDwyer21 @avi_aronov @CarlosDohse Need to add a few more photos to the celebration of @uiccom @UIC_CathLab @UICDom @UICPharm @UICPharmacology @UICPharmacy @StephDwyer21 @VickiGrooPharmD @MSAmbalavanan

[Avi Aronov @avi_aronov]

Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates: A Next ... https://t.co/4tjGYpmzS4

[Avi Aronov @avi_aronov]

Socioeconomics of coronary artery calcium: Is it scored or ignored? - Journal of Cardiovascular Computed Tomography https://t.co/fAA0dNnSRn